TCT-712 Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?
- 1 Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea, Republic of
- 2 The Heart Center of Chonnam National University Hospital, Gwangju, Korea, Republic of
Background
High density lipoprotein (HDL)-cholesterol may play an important role in improving prognosis by cardio-protective effect. However, there are limited data whether the improvement of HDL-C level by pitavastatin (Livalo®) in acute myocardial infarction (AMI) patients (pts) can reduce cardiovascular events or not.
Methods
A total of 404 consecutive AMI pts underwent percutaneous coronary intervention (PCI) with drug eluting stents (DES) from 10 major centers were divided into two groups; the improved HDL-C group (n=162) and the Control group (no improvement in HDL-C level, n=242). All pts were exclusively treated with pitavastatin 2∼4mg/day from the onset of AMI. Improved HDL-C group was defined as increased HDL-C/Total Cholesterol ratio and/or increased HDL-C level from index to 6 months laboratory follow up. Major clinical outcomes up to 12 months were compared between the two groups.
Results
Baseline clinical characteristics were similar between the two groups except the improved HDL-C group showed higher level of triglyceride (146.8 vs. 111.8mg/dl, p<0.001) and lower HDL (39.7 vs. 50.3mg/dl, p<0.001). Procedural success rate and in hospital clinical outcomes were similar between the two groups. At 12 months, major clinical outcomes were not different between the two groups (table).
Conclusions
In AMI pts undergoing PCI with DESs exclusively treated by pitavastatin, improvements in HDL-C Level was not associated with better clinical outcomes.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
댓글 0